ReviewBMJ global health2023
Research priorities for the primordial prevention of acute rheumatic fever and rheumatic heart disease by modifying the social determinants of health.
Review in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Acute rheumatic fever and rheumatic heart disease.Nature reviews. Disease primers · 2026Review
- Development of a multidimensional disease burden assessment system for childhood neuroblastoma based on the social determinants of health theory.Frontiers in oncology · 2026Article
- Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990-2021: a systematic analysis of the global burden of disease study.Clinical rheumatology · 2025Article
- New evidence supports a greater focus on streptococcal skin infections to prevent rheumatic fever.The Medical journal of Australia · 2025Article
- Self-Supervised Multi-Task Learning for the Detection and Classification of RHD-Induced Valvular Pathology.Journal of imaging · 2025Article
- The roles of immuno-modulator treatment and echocardiographic screening in rheumatic fever and rheumatic heart disease control: research from Aotearoa, New Zealand.Journal of the Royal Society of New Zealand · 2025Review
- Global, Regional, and National Burden of Valvular Heart Disease, 1990 to 2021.Journal of the American Heart Association · 2024Article
- Global, Regional, and National Burden of Valvular Heart Disease, 1990 to 2021.Journal of the American Heart Association · 2024Article
- Rheumatic Heart Disease Burden in Africa and the Need to Build Robust Infrastructure.JACC. Advances · 2024Review
- Group A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen.Pathogens (Basel, Switzerland) · 2024Review
- Risk Factors for Acute Rheumatic Disease: Exploring Factors at Individual and Collective Levels.Revista da Sociedade Brasileira de Medicina Tropical · 2024Review
- Prospects for the future: supporting the elimination of rheumatic heart disease - a National Heart, Lung, and Blood Institute Workshop Proceedings.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The social determinants of health (SDH), such as access to income, education, housing and healthcare, strongly shape the occurrence of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) at the household, community and national levels. The SDH are systemic factors that privilege some more than others and result in poverty and inequitable access to resources to support health and well-being. Primordial prevention is the modification of SDH to improve health and reduce the risk of disease acquisition and the subsequent progression to RHD. Modifying these determinants using primordial prevention strategies can reduce the risk of exposure to Group A Streptococcus, a causative agent of throat and skin infections, thereby lowering the risk of initiating ARF and its subsequent progression to RHD.This report summarises the findings of the Primordial Prevention Working Group-SDH, which was convened in November 2021 by the National Heart, Lung, and Blood Institute to assess how SDH influence the risk of developing RHD. Working group members identified a series of knowledge gaps and proposed research priorities, while recognising that community engagement and partnerships with those with lived experience will be integral to the success of these activities. Specifically, members emphasised the need for: (1) global analysis of disease incidence, prevalence and SDH characteristics concurrently to inform policy and interventions, (2) global assessment of legacy primordial prevention programmes to help inform the co-design of interventions alongside affected communities, (3) research to develop, implement and evaluate scalable primordial prevention interventions in diverse settings and (4) research to improve access to and equity of services across the RHD continuum. Addressing SDH, through the implementation of primordial prevention strategies, could have broader implications, not only improving RHD-related health outcomes but also impacting other neglected diseases in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.